Category: Standards

ARMA Policy Position: Prevention of Musculoskeletal Conditions

Arthritis and musculoskeletal conditions affect the bones, joints and muscles, and burdens the lives of so many people.

Musculoskeletal conditions are now the UK’s the biggest cause of pain and disability, accounting for an astounding one-in-five of all visits to the GP. Furthermore, trends indicate that more people than ever will be affected by MSK disorders in the coming years, which is why preventing them has never been more important. For this reason, the Arthritis and Musculoskeletal Alliance (ARMA), an alliance of prominent health charities, professional and research bodies, has produced a Policy Position Paper on Prevention of Musculoskeletal conditions.…

Read more of this article

ARMA Policy Position Paper on Joint Replacement Surgery

In early August, ARMA has published a Policy Position Paper titled:

‘Rationing’ Access to Joint Replacement Surgery and Impact on People with Arthritis and Musculoskeletal Conditions [document opens in pdf]

It deals with the damaging nature of thresholds and scoring tools, the problems of waiting times and restricted access to surgery, and how patients with musculoskeletal conditions are affected.

The Alliance is drawing attention to worrying trends in treatment access and the paper makes clear the key outcomes we are seeking from CCGs and the NHS.

A new addition to the LUPUS UK range of publications

In July LUPUS UK released the newest edition in their range of publications, ‘LUPUS: Bone Health & Osteoporosis’.

The factsheet was kindly written by Dr David Armstrong (Consultant Rheumatologist, Altnagelvin Hospital, Londonderry).

This factsheet can be downloaded from the LUPUS UK website at www.lupusuk.org.uk/publications/ and physical copies are available from the National Office in Romford.

DMARDs guideline for prescriptions and monitoring

The latest guidance is out for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs (DMARDs). It’s aimed at primary and secondary care practitioners managing patients with rheumatic disease in the UK.

Significant updates include:

(1) Harmonisation of monitoring schedules, recommending that all DMARDs that require laboratory monitoring follow the same frequency of testing

(2) More nuanced discussion of the use of methotrexate in lung disease is provided, drawing from the two large meta-analyses recently published.

(3) Significant change is made regarding the evaluation of retinal toxicity for hydroxychloroquine users:

Lead author Dr James Galloway, Senior Clinical Lecturer at King’s College London says:
“These updates have two major focuses: firstly, streamlining monitoring schedules wherever possible, given the myriad of different regimens across drugs, and most of the schedule variations were somewhat arbitrary in their origins; second, to review and incorporate the evidence base available, acknowledging several key publications that have emerged since the first guidance.…

Read more of this article